You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Hepatocellular Carcinoma: Perspective of an Oncologist

Stein, Stacey M. MD

Journal of Clinical Gastroenterology:
doi: 10.1097/MCG.0b013e3182932e6f

The medical oncologist’s perspective on hepatocellular carcinoma (HCC) is unique compared with their view on other solid tumors. A patient’s underlying liver function should be factored into the selection of treatment options; therefore, a staging system that takes into account other clinical parameters other than only tumor characteristics is important. Sorafenib is currently the only FDA-approved chemotherapy drug for patients with HCC based on the data from the SHARP trial. It is important for oncologists to anticipate and treat the side effects of sorafenib treatment in order to help the patients continue the treatment. In addition, it is important to design clinical trials for HCC that have meaningful endpoints to improve our care for patients with HCC.

Author Information

Department of Medicine, Yale University School of Medicine, Section of Medical Oncology, New Haven, CT

S.M.S. has received honoraria from Bayer HealthCare and Onyx Pharmaceuticals Inc.

Reprints: Stacey M. Stein, MD, Department of Medicine, Yale University School of Medicine Section of Medical Oncology, 333 Cedar Street, Room FMP 130, New Haven, CT 06520-8032 (e-mail:

© 2013 by Lippincott Williams & Wilkins